ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update
ReShape Lifesciences (Nasdaq: RSLS) announced it will release its third quarter 2024 financial results on Thursday, November 14, 2024, after market close. The company will host a conference call at 4:30 pm ET the same day, featuring Krishna K. Gupta, current Director of Vyome Therapeutics and future Chairman of the combined company following their previously announced merger. A live webcast will be available on ReShape's website, and participants are encouraged to register and dial in fifteen minutes before the call.
ReShape Lifesciences (Nasdaq: RSLS) ha annunciato che rilascerà i propri risultati finanziari del terzo trimestre 2024 giovedì 14 novembre 2024, dopo la chiusura del mercato. L'azienda ospiterà una conference call alle 16:30 ET dello stesso giorno, con Krishna K. Gupta, attuale Direttore di Vyome Therapeutics e futuro Presidente della società combinata dopo la fusione precedentemente annunciata. Una diretta web sarà disponibile sul sito di ReShape e si incoraggiano i partecipanti a registrarsi e chiamare quindici minuti prima della chiamata.
ReShape Lifesciences (Nasdaq: RSLS) anunció que publicará sus resultados financieros del tercer trimestre de 2024 el jueves 14 de noviembre de 2024, después del cierre del mercado. La empresa llevará a cabo una llamada de conferencia a las 16:30 ET el mismo día, con Krishna K. Gupta, actual Director de Vyome Therapeutics y futuro Presidente de la empresa combinada tras su fusión previamente anunciada. Se ofrecerá una transmisión web en vivo en el sitio de ReShape, y se anima a los participantes a registrarse y llamar quince minutos antes de la llamada.
ReShape Lifesciences (Nasdaq: RSLS)는 2024년 11월 14일 목요일 시장 종료 후 2024년 3분기 재무 결과를 발표할 것이라고 밝혔습니다. 이날 오후 4:30 ET에 Krishna K. Gupta가 참여하는 콘퍼런스 콜도 열릴 예정이며, 그는 Vyome Therapeutics의 현재 이사이자 이전에 발표된 합병 후 결합된 회사의 미래 의장 역할을 맡게 됩니다. ReShape 웹사이트에서 실시간 웨비나가 진행되며, 참가자들은 통화 15분 전에 등록하고 전화에 연결할 것을 권장합니다.
ReShape Lifesciences (Nasdaq: RSLS) a annoncé qu'il publiera ses résultats financiers du troisième trimestre 2024 le jeudi 14 novembre 2024, après la fermeture du marché. La société organisera une conférence téléphonique à 16h30 ET le même jour, avec Krishna K. Gupta, directeur actuel de Vyome Therapeutics et futur président de l'entreprise combinée après leur fusion précédemment annoncée. Une diffusion en direct sera disponible sur le site web de ReShape, et les participants sont encouragés à s'inscrire et à composer le numéro quinze minutes avant l'appel.
ReShape Lifesciences (Nasdaq: RSLS) gab bekannt, dass die finanziellen Ergebnisse des dritten Quartals 2024 am Donnerstag, dem 14. November 2024, nach Börsenschluss veröffentlicht werden. Das Unternehmen wird am selben Tag um 16:30 Uhr ET eine Telefonkonferenz abhalten, in der Krishna K. Gupta, der derzeitige Direktor von Vyome Therapeutics und zukünftige Vorsitzende des fusionierten Unternehmens, nach ihrer zuvor angekündigten Fusion, präsentieren wird. Eine Live-Übertragung wird auf der Website von ReShape verfügbar sein, und die Teilnehmer werden ermutigt, sich anzumelden und fünfzehn Minuten vor der Konferenz einzuwählen.
- None.
- None.
Conference Call to be Held at 4:30 pm ET on Thursday, November 14, 2024
IRVINE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it will report its financial results for the third quarter ended September 30, 2024, including a corporate update on Thursday, November 14, 2024, after market.
Management will host a conference call on Thursday, November 14 at 4:30 pm ET, and will be joined by Krishna K. Gupta, a current Director of Vyome Therapeutics, who will be appointed Chairman of the combined company upon completion of the previously announced merger agreement between the two companies. A live webcast will be available on the “Events and Presentations” section of ReShape’s website at: https://ir.reshapelifesciences.com/events-and-presentations.
To participate in the conference call please register with the following Registration Link, and dial-in details will be provided. Participants using this feature are requested to dial into the conference call fifteen minutes ahead of time to avoid delays.
An archived replay will also be available on the “Events and Presentations” section of ReShape’s website at: https://ir.reshapelifesciences.com/events-and-presentations.
About ReShape Lifesciences®
ReShape Lifesciences® is America’s premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band® System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation™ (DBSN™) system utilizes a proprietary vagus nerve block and stimulation technology platform for the treatment of type 2 diabetes and metabolic disorders. The Obalon® balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. For more information, please visit www.reshapelifesciences.com.
CONTACTS:
ReShape Lifesciences Contact:
Paul F. Hickey
President and Chief Executive Officer
949-276-7223
ir@ReShapeLifesci.com
Investor Relations Contact:
Rx Communications Group
Michael Miller
(917)-633-6086
mmiller@rxir.com
FAQ
When will ReShape Lifesciences (RSLS) report Q3 2024 earnings?
What time is ReShape Lifesciences (RSLS) Q3 2024 earnings call?
Who will be the new Chairman of ReShape Lifesciences (RSLS) after the Vyome merger?
